Title and Organization:
Michael Kauffman is CEO of Karyopharm, which he co-founded with Dr. Sharon Shacham in 2009. He was previously Chief Medical Officer at Onyx Pharmaceuticals, which acquired Proteolix, Inc., both in South San Francisco, California. He was formerly CEO and President of Epix Pharmaceuticals (formerly Predix Pharmaceuticals) - a privately held U.S. company specializing in new drug discovery, screening, and biological modeling integrated with traditional medicinal chemistry. Prior to joining Epix, Michael was Vice President of Medicine and leader of the VELCADE Development Program at Millennium Pharmaceuticals, Inc. He also held senior positions at Millennium Predictive Medicine, Inc. and Biogen Corporation. He is currently on the Boards of Karyopharm, Verastem, Infinity Pharmaceuticals, and Kezar Biosciences. Michael is the author of numerous medical publications and is the publisher and president of OutlineMed Inc., a developer of medical information software. Michael received his BA in biochemistry summa cum laude from Amherst College in 1985 and his MD and PhD in molecular biology from Johns Hopkins Medical School in 1992. He performed his postdoctoral training at Massachusetts General Hospital and Beth Israel Hospital, both part of the Harvard Medical School system. Michael is a 2004 Henry Crown Fellow of The Aspen Institute and a member of the Aspen Global Leadership Network.